Skip to content
drillr.ai
Sign up

LH

Labcorp Holdings Inc.

NYSE · Healthcare · Medical - Equipment & Services · US

$326.89
−1.39%
Ask drillr

  • Sep 3, 2026, 17:59 UTC

    Ultrahuman raised $70 million in a funding round led by Qualcomm Ventures, with participation from Labcorp, Alpha Wave, Blume Ventures, Nexus Venture Partners, Alteria and other investors.

    Source:

  • Aug 24, 2026, 11:02 UTC

    Labcorp announced it will offer the Elecsys pTau-217 blood test, the first FDA-cleared single-biomarker blood test to detect Alzheimer's disease pathology, following FDA clearance.

    Source:

  • Aug 18, 2026, 07:43 UTC

    Labcorp Holdings Inc. shares reached a new 52-week high of $326.89 on Tuesday, trading at $323.18 with a volume of 786,484 shares.

    Source:

  • Aug 14, 2026, 00:00 UTC

    Brian J. Caveney was promoted to Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer of Labcorp Holdings, effective September 1, 2026.

  • Aug 14, 2026, 00:00 UTC

    Megan D. Bailey resigned as Executive Vice President and President, Central Laboratories and International of Labcorp Holdings, effective September 4, 2026.

  • Aug 10, 2026, 11:00 UTC

    The U.S. Food and Drug Administration approved Labcorp's PGDx elio tissue complete CDx as a companion diagnostic to identify advanced melanoma patients with certain BRAF variants eligible for targeted therapies.

    Source:

  • Jul 30, 2026, 10:50 UTC

    Labcorp reported its financial results for the second quarter of 2026, with revenue of $3.73 billion and diluted EPS of $3.64, and raised its full-year 2026 guidance.

    Source:

  • Jul 9, 2026, 21:05 UTC

    Labcorp Holdings Inc. declared a quarterly cash dividend of $0.72 per share of common stock.

    Source:

  • Jun 22, 2026, 11:00 UTC

    Labcorp announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test.

    Source: